Abstract 1223
Background
Parathyroid carcinoma (PC) is a rare endocrine malignancy. Complete surgical resection is the most effective method for the management of PC, however, more than half of PC patients would have recurrent or metastatic lesions. In inoperable disease, treatment options are still limited since chemotherapy and radiotherapy have been generally ineffective in the treatment of PC. Emerging evidence from clinical practice indicated that pre-therapeutic test of molecular biomarkers in tumors may predict the efficacy of the respective targeted drugs. Therefore, understanding the genetic landscape of PC can help in determining whether targeted therapy has potential to be a novel option to treat this refractory disease.
Methods
DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) sections from 19 recurrent or metastatic PC samples. A panel of 560 genes was sequenced with next-generation sequencing (NGS) using Illumina HiSeq X platform to identify genomic alterations at an average sequencing depth of 581×.
Results
A total of 190 genomic alterations were identified. Nine PC samples (47%) harbored at least one potentially actionable genomic alteration including: ROS1 (5/19; 26%), PTEN (3/19; 16%), TSC1 (2/19; 11%), PIK3CA (1/19; 5%), AKT1 (1/19; 5%), MTOR (1/19; 5%), ERBB2 (1/19; 5%), NTRK1 (1/19; 5%), IDH1 (1/19; 5%), and FGFR3 (1/19; 5%). CDC73 mutations were detected in 9/19 (47%) PC samples. Additional recurrent genomic alterations were identified in MSH2 (15/19; 79%), AR (9/19; 47%), BCR (8/19; 42%), SLC45A3 (6/19; 32%), MAGI1 (5/19; 26%), ZNF521 (4/19; 21%), KMT2C (4/19; 21%), and NOTCH4 (4/19; 21%).
Conclusions
The present study identified a considerable frequency of potentially actionable genomic alterations in PC patients for the first time. A series of recurrent mutant genes have been detected as well. The present study would contribute to both selection of novel targeted therapies for PC and further molecular understanding of this refractory malignancy.
Clinical trial identification
Legal entity responsible for the study
Yupei Zhao.
Funding
This work was supported by the Peking Union Medical College Innovative Team Development Program (2016) and the Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine (CAMS-I2M) (2017-I2M-1-001).
Editorial Acknowledgement
None.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4572 - Prospective genome and transcriptome sequencing in advanced-stage neuroendocrine neoplasms
Presenter: Leonidas Apostolidis
Session: Poster Discussion session - NETs and endocrine tumours
Resources:
Abstract
2643 - Synergistic anti-cancer activity of tyrosine kinase inhibitors and paclitaxel with radiation on anaplastic thyroid cancer in vitro and in vivo
Presenter: Yong Sang Lee
Session: Poster Discussion session - NETs and endocrine tumours
Resources:
Abstract
2264 - Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC)
Presenter: Bhumsuk Keam
Session: Poster Discussion session - NETs and endocrine tumours
Resources:
Abstract
2867 - Health-related quality of life (HRQoL) for octreotide long-acting (oct l-a) vs. placebo (PBO) in patients (pts) with metastatic midgut neuroendocrine tumors (mmNETs) in the phase IIIb PROMID trial
Presenter: Anja Rinke
Session: Poster Discussion session - NETs and endocrine tumours
Resources:
Abstract
1156 - Everolimus after transarterial liver therapy of metastases from gastrointestinal neuroendocrine tumors: the FFCD 1104-EVACEL-GTE phase II study
Presenter: Thomas Walter
Session: Poster Discussion session - NETs and endocrine tumours
Resources:
Abstract
2551 - A phase II study of everolimus in patients with unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-contained chemotherapy
Presenter: Hiroyuki Okuyama
Session: Poster Discussion session - NETs and endocrine tumours
Resources:
Abstract
Poster Discussion session - NETs and endocrine tumours - Invited Discussant 1311PD, 1312PD and 1313PD
Presenter: Enrique Grande
Session: Poster Discussion session - NETs and endocrine tumours
Resources:
Slides
Webcast
Poster Discussion session - NETs and endocrine tumours - Invited Discussant 450PD and 1310PD
Presenter: Aldo Scarpa
Session: Poster Discussion session - NETs and endocrine tumours
Resources:
Slides
Webcast
Poster Discussion session - NETs and endocrine tumours - Invited Discussant 1820PD and 1821PD
Presenter: Rossella Elisei
Session: Poster Discussion session - NETs and endocrine tumours